Abstract:Objectives This prospective clinical study aimed to evaluate the vascularization characteristics of low-risk gestational trophoblastic neoplasia (GTN) using Doppler imaging and to develop a predictive model for resistance to methotrexate (MTX). Methods Patients with low-risk GTN receiving primary MTX treatment were enrolled from the Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China, from September 2012 to August 2018. The primary endpoint was to develop and internally validate a predictive model for resistance to MTX therapy in these patients. In the training set, clinical features and Doppler hemodynamic parameters before MTX therapy were analyzed using logistic regression to identify independent predictors of MTX resistance, which were integrated into the model. The predictive performance of the model was evaluated by leave-one-out cross-validation in the training dataset and internal validation in an independent-sample test dataset. Results The entire imaging protocol was completed by 147 eligible patients, of which 110 comprised the training set and 37 the test set. In the training set, cases with myometrial invasion (81.8%; 90/110) showed vascular-enriched areas in the myometrium and high velocity and low impedance ratios of the uterine artery (UtA) compared to cases without myometrial invasion (18.2%; 20/110). On multivariate logistic regression analysis, time-averaged mean velocity in UtA (UtA-TAmean) and the International Federation of Gynecology and Obstetrics (FIGO) score were identified as independent predictors (P = 0.009 and P = 0.043, respectively) of MTX resistance. The Doppler-based predictive model, developed based on the 90 cases with myometrial invasion, was y = -2.95332 + 0.41696 x FIGO score + 0.03551 x UtA-TAmean. The model showed an area under the curve of 0.757 (95% CI, 0.653-0.862) and the optimal cut-off value was 0.50622, which had 45.2% sensitivity and 96.6% specificity. The model stratified patients with low-risk GTN into low (< 10%), intermediate (10-90%) and high (> 90%) probability of MTX resistance, based on the threshold values of -1.59544 and 0.10046. The model had an accuracy of 74.4% (95% CI, 64.5-82.3%) in the cross-validation and 72.7% (95% CI, 55.8-84.9%) in the internal validation. Conclusions The Doppler-based predictive model, combining a non-invasive marker of tumor vascularity with the FIGO scoring system, can differentiate cases with low from those with high probability of developing MTX resistance and therefore has the potential to guide treatment options in patients with low-risk GTN and myometrial invasion. (c) 2020 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies

Direct Comparisons of Efficacy and Safety Between Actinomycin-D and Methotrexate in Women With Low-Risk Gestational Trophoblastic Neoplasia: A Systematic Review and Meta-Analysis

The Efficacy and Safety of First-Line Single-Agent Chemotherapy Regimens in Low-Risk Gestational Trophoblastic Neoplasia: A Network Meta-Analysis.

The 16-Year Experience in Treating Low-Risk Gestational Trophoblastic Neoplasia Patients with Failed Primary Methotrexate Chemotherapy

[Single Methotrexate Chemotherapy for Low-Risk Gestational Trophoblastic Tumor].

[Curative Effects and Influenced Factors of Primary Chemotherapy with Single-Agent Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia].

Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0–4): study protocol for a prospective, multicentre, randomized trial

Low-risk Gestational Trophoblastic Neoplastic Outcome after Primary Treatment with Low-Dose Methotrexate from 2005 to 2017

Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial

[Effects of Primary Chemotherapy with Single Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia and Influencing Factors Thereof].

Comparison of Pulsed Actinomycin D and 5‐day Actinomycin D As First‐line Chemotherapy for Low‐risk Gestational Trophoblastic Neoplasia

Risk Factors for Methotrexate Resistance in Low-Risk Gestational Trophoblastic Neoplasia Patients (FIGO Score 0-4)

First-line monodrug chemotherapy in low-risk gestational trophoblastic neoplasia: a network meta-analysis

Hotspots of Low-Risk Gestational Trophoblastic Neoplasia Treatment

Doppler-based predictive model for methotrexate resistance in low-risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients

Ema-Co Chemotherapy for High-Risk Gestational Trophoblastic Neoplasia: A Clinical Analysis of 54 Patients

Factors Predicting Severe Myelosuppression and Its Influence on Fertility in Patients with Low-Risk Gestational Trophoblastic Neoplasia Receiving Single-Agent Methotrexate Chemotherapy.

The Effect of the Plasma Methotrexate Concentration During High-Dose Methotrexate Therapy in Childhood Acute Lymphoblastic Leukemia.

Low-risk Gestational Trophoblastic Neoplasia Outcome after Treatment with VMP Regimen from 2005 to 2017.

Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma

The Effectiveness of Letrozole Alone or in Combination with Methotrexate in the Management of Ectopic Pregnancy, A Systematic Review and Meta-Analysis